智通财经APP获悉，欧盟药品监管机构欧洲药品管理局(EMA)的一个专家组已经确定，礼来(LLY.US)的减重药Mounjaro治疗阻塞性睡眠呼吸暂停(OSA)不需要单独的适应证。 人用医药产品委员会(CHMP)认为，Mounjaro的使用已被批准的体重管理适应证所涵盖，不需要单独的适应证 ...

There have also been global shortages of weight loss drugs, Novo Nordisk’s Wegovy/Ozempic (semaglutide) and Eli Lilly’s Zepbound/Mounjaro (tirzepatide). The EMA was given a formal, legal role ...

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

According to the EMA, there has been one case each of suicidal ... for diabetes and dual GIP/GLP-1 agonist Mounjaro (tirzepatide), which is approved for diabetes and in late-stage development ...